Stockscreener 앱 받기
25.16
2.25%
-0.58
전일 마감가:
$25.74
열려 있는:
$26.02
하루 거래량:
566.81K
Relative Volume:
0.73
시가총액:
$1.16B
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
17.35
EPS:
1.45
순현금흐름:
$173.19M
1주 성능:
-1.10%
1개월 성능:
+10.16%
6개월 성능:
+81.66%
1년 성능:
-15.29%
1일 변동 폭
$25.09
$26.17
1주일 범위
$25.09
$26.89
52주 변동 폭
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
813-553-6680
주소
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
PCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.16 | 1.16B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. LawsuitPCRX - ACCESS Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - PR Newswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel ... - The Bakersfield Californian
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX - GlobeNewswire Inc.
Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class ActionPCRX - Morningstar
Class Action Filed Against Pacira BioSciences, Inc. (PCRX)March 14, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - ACCESS Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Pacira to Report 2024 Financial Results on Thursday February 27, 2025 - GlobeNewswire
Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your RightsPCRX - PR Newswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. - GlobeNewswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesPCRX - PR Newswire
Investors who lost money on Pacira BioSciences, Inc. (PCRX) - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel ... - The Bakersfield Californian
Lost Money on Pacira BioSciences, Inc.(PCRX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - GuruFocus.com
Yousif Capital Management LLC Has $340,000 Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Zacks Research Issues Positive Outlook for PCRX Earnings - MarketBeat
Zacks Research Issues Pessimistic Forecast for PCRX Earnings - MarketBeat
PCRX Shareholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - Markets Insider
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $22.78 Consensus Price Target from Analysts - MarketBeat
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $22.78 - Defense World
Shares Of Pacira BioSciences Inc (NASDAQ: PCRX): Are They Overvalued Compared To Others? - Stocks Register
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - StreetInsider.com
What is Zacks Research’s Estimate for PCRX FY2024 Earnings? - Defense World
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira - PR Newswire
Empowered Funds LLC Buys 11,149 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Pacira BioSciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - Morningstar
Q4 EPS Estimate for Pacira BioSciences Boosted by Analyst - Defense World
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Marketscreener.com
The Gross Law Firm Reminds Pacira BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025PCRX - Morningstar
Lawsuit Alert: Investors in shares of Pacira BioSciences, Inc. - openPR
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel - The Bakersfield Californian
A Guide To The Risks Of Investing In Pacira BioSciences Inc (PCRX) - Knox Daily
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 14, 2025 to Discuss Your RightsPCRX - PR Newswire
Shareholders that lost money on Pacira BioSciences, - GlobeNewswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Janney Montgomery Scott LLC - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira - GlobeNewswire
Pacira BioSciences Inc (PCRX) Shares Decline Despite Market Challenges - The News Heater
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - PR Newswire
PCRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Is Pacira BioSciences Inc (PCRX) a good investment opportunity? - US Post News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.23%
3.94%
자본화:
|
볼륨(24시간):